HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anna deFazio Selected Research

Neoplasms (Cancer)

1/2021Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.
10/2020ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
1/2019PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
11/2018BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition.
1/2018Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.
1/2018Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
1/2018Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
5/2017Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium.
4/2017Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
1/2017History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anna deFazio Research Topics

Disease

28Neoplasms (Cancer)
01/2021 - 05/2002
26Ovarian Neoplasms (Ovarian Cancer)
01/2021 - 11/2008
9Carcinoma (Carcinomatosis)
01/2021 - 02/2009
7Ovarian Epithelial Carcinoma
01/2019 - 03/2011
5Breast Neoplasms (Breast Cancer)
01/2019 - 10/2002
2Endometrioid Carcinoma
04/2014 - 08/2013
1Prostatic Neoplasms (Prostate Cancer)
01/2020
1Sarcoma (Soft Tissue Sarcoma)
11/2018
1Endometriosis
05/2017
1Cysts
03/2011
1Inflammation (Inflammations)
03/2011
1Sleep Initiation and Maintenance Disorders (Insomnia)
12/2009
1Adenocarcinoma
11/2008
1Endometrial Stromal Sarcoma
04/2004

Drug/Important Bio-Agent (IBA)

7PlatinumIBA
01/2018 - 05/2002
5Biomarkers (Surrogate Marker)IBA
01/2019 - 08/2013
5DNA (Deoxyribonucleic Acid)IBA
07/2013 - 02/2009
3Adenosine Triphosphate (ATP)IBA
10/2020 - 05/2014
3Paclitaxel (Taxol)FDA LinkGeneric
01/2019 - 05/2014
3Proteins (Proteins, Gene)FDA Link
01/2017 - 02/2009
3Hormones (Hormone)IBA
08/2013 - 10/2002
2Carboplatin (JM8)FDA LinkGeneric
01/2021 - 12/2015
2ChromatinIBA
01/2021 - 12/2016
2taxaneIBA
01/2018 - 02/2016
2Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2018 - 07/2012
2Oral ContraceptivesIBA
05/2017 - 04/2014
2Small Interfering RNA (siRNA)IBA
04/2011 - 11/2008
1Biological ProductsIBA
10/2020
1Peptides (Polypeptides)IBA
01/2020
14- (4- dihexadecylaminostyryl)- N- methylpyridium (DiA)IBA
01/2020
1Pharmaceutical PreparationsIBA
01/2019
1Estrogen ReceptorsIBA
01/2019
1Anastrozole (Arimidex)FDA LinkGeneric
01/2019
1paragonIBA
01/2019
1CA-125 Antigen (CA 125 Antigen)IBA
11/2018
1Mitogen-Activated Protein KinasesIBA
11/2018
1dabrafenibIBA
11/2018
1TransducinIBA
01/2018
1Retinoblastoma ProteinIBA
01/2018
1rucaparibIBA
01/2018
1Thymidylate SynthaseIBA
01/2018
1cyclo(Arg-Pro) (CI 4)IBA
05/2017
1AntigensIBA
05/2017
1Glycoproteins (Glycoprotein)IBA
05/2017
1Analgesics (Analgesic Drugs)IBA
04/2017
1Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
04/2017
1UbiquitinIBA
12/2016
1Ligases (Synthetase)IBA
12/2016
1Genetic Markers (Genetic Marker)IBA
03/2016
1Membrane Proteins (Integral Membrane Proteins)IBA
02/2016
1MicroRNAs (MicroRNA)IBA
01/2016
13' Untranslated Regions (3' UTR)IBA
01/2016
1Histones (Histone)IBA
12/2015
1Indicators and Reagents (Reagents)IBA
12/2014
1Subfamily A ATP Binding Cassette TransporterIBA
07/2014
1LipidsIBA
07/2014
1CholesterolIBA
07/2014
1Transcription Factors (Transcription Factor)IBA
07/2014
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
07/2014
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
07/2014
1Transforming Growth Factor beta3 (TGF beta 3)IBA
04/2014
1Galectin 1 (LGALS1)IBA
04/2014
1betaglycan (TGFBR3)IBA
04/2014
1Transforming Growth Factor-beta Type I ReceptorIBA
04/2014
1Interleukin-6 (Interleukin 6)IBA
04/2014
1Interleukin-15 (Interleukin 15)IBA
04/2014
1Interleukin-8 (Interleukin 8)IBA
04/2014
1Interleukin-10 (Interleukin 10)IBA
04/2014
1liposomal doxorubicin (Doxil)FDA Link
08/2012
1Epithelial Cell Adhesion MoleculeIBA
03/2011
1Telomerase (Telomerase Reverse Transcriptase)IBA
07/2010
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
12/2009
1OligonucleotidesIBA
02/2009
1Cisplatin (Platino)FDA LinkGeneric
11/2008
1villinIBA
06/2008
1Arginine (L-Arginine)FDA Link
06/2008
1Keratin-8 (Keratin 8)IBA
06/2008
1CalciumIBA
06/2008
1Progestins (Progestagens)IBA
04/2004
1Protein Isoforms (Isoforms)IBA
04/2004
1progesterone receptor AIBA
04/2004
14-phenylbutyric acid (Buphenyl)FDA Link
10/2002
1Butyrates (Butyrate)IBA
10/2002

Therapy/Procedure

12Drug Therapy (Chemotherapy)
01/2021 - 05/2002
6Therapeutics
01/2018 - 04/2004
2Cytoreduction Surgical Procedures
02/2016 - 12/2015
1Aftercare (After-Treatment)
01/2018
1Tubal Sterilization (Tubal Ligation)
05/2017
1Combination Drug Therapy (Combination Chemotherapy)
05/2015
1Chemoprevention
10/2002